---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-054498"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:10:25.183508+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbCellera announces U.S. government purchase of 614,000 doses of bamlanivimab/etesevimab for $1.29B

## Summary
- Lilly will supply 614,000 additional doses no later than January 31, 2022; minimum 400,000 by December 31, 2021.
- Total agreement value is $1.29 billion for bamlanivimab with etesevimab, discovered by AbCellera.
- The antibody therapy has treated over 535,000 patients in the U.S., potentially preventing 25,000 hospitalizations.
- AbCellera receives royalties from Lilly on sales of bamlanivimab and etesevimab.

## SEC filing metadata
- accession: 0001564590-21-054498
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459021054498/0001564590-21-054498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459021054498/abcl-8k_20211102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-054498
- JSON: https://secwatch.observer/filing/0001564590-21-054498.json
- Plain text: https://secwatch.observer/filing/0001564590-21-054498.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.